Abstract Body

Background: HIV-positive individuals may be at increased risk of cognitive impairment (CI). The contribution of HIV-, antiretroviral treatment- and non-HIVrelated risk factors towards CI remains to be clarified further. Methodology: 103 HIV-infected men with suppressed viraemia on cART for ≥12 months and 75 uninfected male controls (comparable regarding age, ethnicity, IQ and education), all aged ≥45 and participating in the AGEhIV cohort study, underwent neuropsychological assessment (covering fluency, attention, information processing speed, executive function, memory and fine motor function). CI was assessed using Frascati criteria and by multivariate normative comparison (MNC), a novel and more accurate technique for evaluating cognitive impairment (CI). MNC was used to compare all cognitive test scores jointly from each HIV-positive individual with the distribution of scores from the total uninfected control group. The false positive rate (alpha) was set at 5% one-tailed, providing a specificity of at least 95%. Multiple logistic regression was used to identify determinants for CI. Results: The numbers of participants with CI in each group using either Frascati criteria or MNC are shown in the Table. Adjusting for age, education and native language, depressive symptoms remained borderline significantly associated with CI by both methods, whereas HIV-status did not. In HIV-positive men after adjusting for the same parameters, depressive symptoms, years spent with CD4 counts <350 cells/mm3 and higher soluble CD163 levels, were independently associated with CI, both by Frascati criteria and MNC. A lower central nervous system penetration effectiveness (CPE) score was independently associated with CI, but only when applying Frascati criteria. Risk factors that were not significantly associated with CI are listed in the Table. Conclusions: The presence of depressive symptoms was associated with cognitive impairment, and in HIV-infected men with suppressed viraemia on cART, together with a longer time spent with reduced CD4 counts and evidence of increased innate immune activation contributed to the risk of CI, regardless of the method by which CI was assessed. The contribution of the CPE score was less consistent.